Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRICARDIA is an over-the-counter dietary supplement developed and marketed by MMeditech (Meditec). It is formulated as a combination of three essential B-vitamins: folic acid (Vitamin B9), pyridoxine (Vitamin B6), and cyanocobalamin (Vitamin B12). The product is primarily indicated for the management of hyperhomocysteinemia and the promotion of cardiovascular health. Elevated levels of homocysteine are a recognized risk factor for the development of atherosclerosis, coronary heart disease, and stroke. TRICARDIA works by providing the necessary enzymatic cofactors for the remethylation and transsulfuration pathways, which convert homocysteine into methionine and cysteine, respectively, thereby lowering its concentration in the blood.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TRICARDIA.